Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) Sees Large Decrease in Short Interest

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) was the recipient of a large drop in short interest during the month of August. As of August 14th, there was short interest totaling 770 shares, a drop of 79.5% from the July 30th total of 3,749 shares. Approximately 0.0% of the company’s shares are sold short. Based on an average trading volume of 34,611 shares, the days-to-cover ratio is currently 0.0 days.

Analysts Set New Price Targets

Several brokerages have issued reports on BOLT. Weiss Ratings reissued a “sell (e+)” rating on shares of Bolt Biotherapeutics in a research note on Friday, July 17th. Rodman & Renshaw started coverage on Bolt Biotherapeutics in a research note on Thursday, May 28th. They set a “buy” rating and a $22.00 target price on the stock. Finally, HC Wainwright reiterated a “buy” rating and issued a $7.00 price target on shares of Bolt Biotherapeutics in a report on Thursday, May 28th. Two investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Hold” and an average target price of $14.50.

Bolt Biotherapeutics Trading Down 2.2%

Shares of NASDAQ BOLT traded down $0.09 during mid-day trading on Friday, reaching $3.91. The company had a trading volume of 13,204 shares, compared to its average volume of 25,518. The business’s 50-day moving average is $3.90 and its 200-day moving average is $4.41. The company has a current ratio of 2.61, a quick ratio of 2.61 and a debt-to-equity ratio of 1.47. The stock has a market cap of $7.55 million, a price-to-earnings ratio of -0.24 and a beta of 1.18. Bolt Biotherapeutics has a 52 week low of $3.13 and a 52 week high of $7.20.

Bolt Biotherapeutics (NASDAQ:BOLT) last announced its quarterly earnings data on Tuesday, August 11th. The company reported ($4.57) earnings per share for the quarter, missing analysts’ consensus estimates of ($3.39) by ($1.18). The company had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.50 million. Bolt Biotherapeutics had a negative net margin of 611.47% and a negative return on equity of 126.23%. Equities analysts expect that Bolt Biotherapeutics will post -11.1 earnings per share for the current year.

Institutional Trading of Bolt Biotherapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Squarepoint Ops LLC boosted its holdings in shares of Bolt Biotherapeutics by 19.8% in the third quarter. Squarepoint Ops LLC now owns 14,836 shares of the company’s stock valued at $79,000 after purchasing an additional 2,448 shares during the period. Shay Capital LLC bought a new stake in Bolt Biotherapeutics during the 3rd quarter valued at $85,000. Susquehanna International Group LLP bought a new stake in Bolt Biotherapeutics during the 3rd quarter valued at $89,000. Nano Cap New Millennium Growth Fund L P purchased a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth $112,000. Finally, T3 Companies LLC purchased a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth $208,000. Institutional investors own 86.70% of the company’s stock.

Bolt Biotherapeutics Company Profile

Bolt Biotherapeutics is a clinical-stage immuno-oncology company focused on developing novel targeted therapies that engage both innate and adaptive immune responses against cancer. The company’s proprietary Biologics-Driven Checkpoint (BDC) platform combines tumor-targeting antibodies with innate immune agonists to activate antigen-presenting cells within the tumor microenvironment, thereby promoting robust T-cell mediated tumor cell killing. Its lead candidate, BDC-1001, couples a HER2-directed monoclonal antibody with a Toll-like receptor 7/8 agonist and is currently in Phase I clinical trials for HER2-positive solid tumors.